Please assess the completion status of the following clinical trial:

Trial Title: A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* BMI within 18.0 to 33.0 kg/m2, inclusive (minimum weight of 50.0 kg at Screening)~* Healthy, as determined by no clinically significant medical history, physical examination findings, 12-lead ECG findings, vital signs measurements, and laboratory results at screening, as judged by the investigator~* Current opioid users who had used oral opioids for recreational (non-therapeutic) purposes, at least 10 times in the past year~Exclusion Criteria:~* Drug or alcohol dependence within the last 12 months (except nicotine)~* Subjects who had ever been in treatment for substance use disorders (except smoking cessation~* History of presence of any clinically significant cardiac, neurologic, pulmonary, psychiatric, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, dermatologic, renal, or other major disease at screening, which in the opinion of the investigator, would have jeopardized the safety of the subject or the validity of the study results~* History or presence of hypotension, judged to be clinically significant based on investigator judgement

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A:CL-108 22.5mg/975mg/37.5mg (Type: EXPERIMENTAL): CL-108 22.5 mg/975 mg/37.5 mg tablet by mouth
- Treatment B:CL-108 37.5mg/1625mg/62.5mg (Type: EXPERIMENTAL): CL-108 37.5 mg/1625 mg/62.5 mg tablet by mouth
- Treatment C:M366 22.5mg/975mg (Type: ACTIVE_COMPARATOR): M366 22.5 mg/975 mg tablet by mouth
- Treatment D: M366 37.5mg/1625mg (Type: ACTIVE_COMPARATOR): M366 37.5 mg/1625 mg tablet by mouth
- Treatment E: Placebo (Type: PLACEBO_COMPARATOR): Placebo 0 mg tablet by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).